Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

47.25 +0.40 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios
These two Cathie Wood holdings are great long-term buys. 
Via The Motley Fool
Got $100? 2 Top Cathie Wood Stocks to Buy and Hold.
These stocks are steals right now. 
Via The Motley Fool
Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements
Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio. 
Via InvestorPlace
Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. (NASDAQ: SGRY). "That industry has been up and down and up and down," he added. 
Via Benzinga
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
Bull markets generally favor growth stocks, so now is a great time to buy quality growth players. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
CRISPR Therapeutics shares have soared 39% over the past three months. 
Via The Motley Fool
Is CRISPR Therapeutics a Buy in the New Bull Market?
CRISPR Therapeutics is a specialist in the hot technology of gene editing. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
Wood added to her existing positions in these three exciting companies. 
Via The Motley Fool
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions. 
Via InvestorPlace
These 5 growth stocks are now in buy ranges
Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs. 
Via MarketBeat
Topics ETFs
Where Will CRISPR Therapeutics Be in 5 Years?
The company could maintain the momentum it gained last year. 
Via The Motley Fool
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
Despite A bump in the road, the biotech's future looks sunny. 
Via The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
Has investing in Vertex been a better option than just putting your money in the S&P 500? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase. 
Via Investor's Business Daily
Topics ETFs
Could Editas Medicine Become the Next CRISPR Therapeutics?
The similarities between the pair are striking, but it might not be enough. 
Via The Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Both companies are going to continue doing high-impact science in 2024. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026
Discover the trailblazing strategies of three tech stocks that are reshaping industries through innovation, adaptability and revenue surges. 
Via InvestorPlace
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
Via Benzinga
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Exposures Product Safety
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units. 
Via Benzinga
Topics ETFs
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. 
Via Investor's Business Daily
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
These risky stocks can deliver big returns for investors. 
Via The Motley Fool
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
Key regulatory developments sent this biotech stock higher. 
Via The Motley Fool
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
An acquisition could be both a blessing and a curse for long-term investors. 
Via The Motley Fool
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.